Hypros Group Completes Hundreds of Millions of Yuan in Series D Financing

Visit the original URL

Chuangyebang was informed that Hypros Group recently completed the D round of financing, and the total amount of this round of financing amounted to several hundred million yuan. This round was jointly led by SoftBank China Capital and Tongrentang Pension Investment, and followed by well-known investment institutions such as CNCB Capital. The funds will be used to further promote the research and development of the company’s tumor liquid biopsy technology and bioinformatics analysis technology, the layout of the application and registration reserves of IVD products, as well as product marketing promotion and channel expansion. PricewaterhouseCoopers Corporate Finance and M&A acted as exclusive financial advisor to the transaction.

Previously, Hypros Group has been favored by professional investment institutions such as Pangu Venture Capital, Softbank China Capital, Shenzhen Venture Capital, Preferred Capital, Shanlan Capital, and Yifeng Capital. In this round, the well-known investment institution SoftBank China Capital added additional financial support, and Tongrentang Pension Investment, a subsidiary of the “time-honored Chinese medicine brand” Tongrentang, and CNCB Capital, an overseas investment banking platform, participated in the investment, which fully proves the recognition of the growth and development prospects of Hypros from all walks of life. Provide financial support for the research and development of innovative products and expand the market territory, help Hypros to deeply cultivate the tumor precision medicine and genetic big data industry, and make steady progress on the road of high-quality development.

Xu Mingyan, founder and chairman of Hypros, said: “I am very grateful to the new round of investment institutions for their recognition and support of Hypros, and I am especially grateful to SoftBank China Capital and previous investors for their continuous support! Over the past eight years, Hypro has Loss is deeply involved in the three major fields of tumor management, genetic disease screening and major infectious diseases. We will always be patient-first, customer-centric, and continuous striver-oriented, and continue to pursue innovation in technology, products and services. Always adhere to quality first, bring more innovative medical value to customers, and strive to become a world-leading life technology company. Here, I would also like to express my special thanks to the governments, partners and friends from all walks of life who have always cared about and supported us.”

Liu Ying, partner of SoftBank China Capital, said: “We are firm and continue to be optimistic about Hypros, on the one hand because we have firm confidence in the long-term development of genetic technology and the field of big health, and on the other hand, we also fully agree with the technology direction of the company’s team. The original intention of goodness and recognition of the tenacity of the “Naval Spirit” that the team has shown over the past few years.

The Hypros team has always adhered to science and technology, diversified development, and continued to provide patients with high-quality testing through high-quality products and reliable services. I also believe that in the post-epidemic era, Hypros will continue to deliver reliable and innovative products to users and the society, bring value to shareholders, and continue to grow into an excellent life science leader. “

Hu Renhua, general manager of Tongrentang Pension Investment, said: “Hypros has successively deployed three major business segments: tumor whole-course management, genetic disease screening, and pathogenic microorganism detection. Stand out from the fierce competition! We believe that with the acceleration of the internal R&D pipeline, the further recognition of the external market and the effective assistance of capital, the company will make greater breakthroughs in technology and business, and create greater value for shareholders and society. Grow into a leading company in the industry!”

Li Lining, executive partner of the Life Science Division of Pangu Venture Capital, said: “Hypros has been deeply involved in the management of the entire course of tumors and has served hundreds of thousands of patients. A number of NGS and PCR products, as well as a number of bioinformatics analysis systems and medical inspection service process management systems, have been used and praised by hospitals and peers. In recent years, several products have been launched in the field of pathogenic microorganisms and personal genome detection, showing that the company A corporate culture of active innovation, rapid response, and efficient team collaboration.”

Chen Shifu, co-founder and chief technology officer of Hypros said: “In the past eight years since its establishment, Hypros has deeply integrated advanced biotechnology and information technology to provide users with high-quality detection products and open source a large number of excellent bioinformatics software to the industry. , and provided technical support and detection guarantee in the repeated anti-epidemic. In the new journey, Hypros will use AI technology as the axis, integrate multi-level data such as genes, pathology and imaging, and explore the application of multi-scale omics in clinical practice. We will continue to strengthen the advantages of ultra-micro tumor liquid biopsy technology, deeply cultivate the molecular detection technology in the whole course of tumor management, and explore the most suitable solutions for early screening and monitoring of tumors.

At the same time, we will continue to consolidate our advantages in the “BT+IT” field, provide inspection institutions with systematic solutions that have been forged and polished, create a smart inspection system, and provide a package of solutions for the real NGS clinical implementation. We will take science and technology as the starting point to fight the epidemic, adhere to science and technology for the people, have the courage to take responsibility, and continue to improve the quality of the “Hippu Iron Army” in the field of public health services.

Lu Jian, General Manager of the Equity Investment Department of Tongrentang Pension Investment, said: “Hypros started a business for a team of scientists and created strong technical and social benefits at the same time. With the excellent sensitivity and specificity of the product, it can be used in medication guidance. It is a leader in terms of scientific research and guidance; at the same time, it is planning a layout in the field of early screening, and the concept of “preventing disease” conforms to the interests of the whole people; Hypros products and services are not only conducive to the treatment of “gastrointestinal” and “bone marrow” diseases, but also to prevent diseases caused by “Rioli”.”

Chen Chun, Partner, Head of Corporate Finance and M&A, Southern China, and Zhang Pingping, Partner of the Greater Bay Area, PwC said: “First of all, congratulations to Hypros on the successful completion of this round of financing, we are very honored to be able to participate and contribute. ProLogis has a profound technical accumulation in the detection of tumors, genetic diseases and pathogenic microorganisms, providing high-quality services and strong support for disease prevention and control of the majority of residents and scientific research in medical institutions. At the same time, Hypros also has strong The sense of social responsibility has made a huge contribution to the new crown detection.

Hypros emphasizes research and development and technology, and continuously introduces advanced management and operation experience. Its financial performance has grown rapidly, and it has established its own capital market attractiveness in many aspects. In this financial advisory service, PwC deployed the most professional medical industry team and established a long-term strategic partnership with the company. PwC also looks forward to further cooperation with the company in the future to continue to assist the company’s capital market development. “

attached

For more project information, please go to ” Analysis of Rui Beast “.

media coverage

Venture State Investment Community Investment Network
Related events

This article is reprinted from: https://readhub.cn/topic/8hXtvpfHoug
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment